Clinical trial Recruiting at 1 site Interventional Ages 12 to 21

Using domperidone to help young people with severe stomach issues

Official title: Compassionate Use of Domperidone for Refractory Gastroparesis

Run by Children's Mercy Hospital Kansas City · NCT04699591 · Data updated 2026-11-12

This study is testing if the medication domperidone can help young people aged 12 to 21 with severe stomach problems that haven't improved with other treatments.

Quick facts

Study typeInterventional
Ages12 Years to 21 Years
SexAll
Enrollment20 (estimated)
SponsorChildren's Mercy Hospital Kansas City
Academic / other
Locations1 site (Kansas City, Missouri)
StatusRecruiting
StartedApril 2013
Main results expectedDecember 2035
Study endsDecember 2035
Registry record updatedMarch 24, 2026
Trial IDNCT04699591 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are males and females aged 12 to 21 with severe gastrointestinal symptoms that have not responded to standard therapies.

Probably not a fit

Patients who have not been evaluated for other causes of their symptoms or those who are not within the specified age range may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program allows children aged 12 to 21 with refractory gastroparesis and GERD symptoms to receive domperidone after failing standard treatments. Participants will undergo a thorough medical evaluation, including physical exams and ECGs, to ensure safety before starting the medication. Domperidone will be administered four times daily, with regular follow-ups to monitor health and medication effects. The study aims to provide a potential solution for those suffering from severe gastrointestinal motility disorders.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for young patients suffering from refractory gastroparesis and GERD.

How similar studies have gone: While the use of domperidone has been explored in other contexts, this specific application for refractory gastroparesis in a pediatric population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female
2. Age 12 - 21
3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.
4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:

   * increased prolactin levels
   * extrapyramidal side effects
   * breast changes
   * Cardiac arrhythmias including QT prolongation
   * There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)
   * The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.

Exclusion Criteria:

1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\> 450 milliseconds for males, QTc\>470 milliseconds for females).
3. Clinically significant electrolyte disorders.
4. Gastrointestinal hemorrhage or obstruction
5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).
6. Pregnant or breast feeding female
7. Known allergy to domperidone

Where it's running

  • Children's Mercy Hospitals and Clinics
    Kansas City, Missouri, United States
    Recruiting

Study contacts

  • Principal investigator: Jose Cocjin, MD — Children's Mercy Hospital Kansas City
  • Study coordinator: Corey Schurman, MA, CCRC
  • Email: crschurman@cmh.edu
  • Phone: 816-302-3076

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.